NCT04408079View on ClinicalTrials.gov

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

October 31, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

TQB3558

TQB3558 is a kinase inhibitor of the TRK protein family.

Trial Locations (1)

200233

RECRUITING

Shanghai Sixth People's Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY